miR-181a在卵巢癌细胞中对顺铂的耐药作用

徐丽秀; 美力班·吐尔逊; 克热曼·牙库甫

doi:10.12259/j.issn.2095-610X.S20220131

miR-181a在卵巢癌细胞中对顺铂的耐药作用

doi: 10.12259/j.issn.2095-610X.S20220131

1.
新疆医科大学基础医学院，新疆乌鲁木齐　830001
2.
新疆维吾尔自治区人民医院妇科，新疆乌鲁木齐　830001

基金项目: 新疆高发肿瘤宫颈癌基础研究创新团队基金资助项目（2021D14002）

详细信息

作者简介:
徐丽秀（1992～），女，山东青岛人，在读博士研究生，主要从事妇科肿瘤基础工作

通讯作者:
克热曼·牙库甫，E-mail：771432636@qq.com

中图分类号: R737.31
计量
- 文章访问数: 3119
- HTML全文浏览量: 1853
- PDF下载量: 32
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-26
- 网络出版日期: 2021-12-20
- 刊出日期: 2022-01-15

Studies on Cisplatin Resistance of miR-181a in Ovarian Cancer Cells

1.
Basic Medicine College of Xinjiang Medical University，Urumqi Xinjiang，830011
2.
Dept. of Gynecology People’s Hospital of Xinjiang Uygur Autonomous Region，Urumqi Xinjiang，830001

摘要

摘要: 目的探讨miR-181a在卵巢癌化疗抵抗方面的影响及其机制。方法 qRT-PCR检测卵巢癌细胞A2780及A2780/DDP中miR-181a的表达；对A2780及A2780/DDP细胞分别进行miR-181a mimics和inhibitors的转染，并利用qRT-PCR技术验证；MTT法检测转染前后细胞对顺铂的敏感性，利用TargetScan、miRDB与miRwalk 3个MicroRNA靶基因数据库预测miR-181a下游靶点，并通过Western blot技术分析预测基因的表达。结果与A2780细胞相比，miR-181a在A2780/DDP细胞中的表达明显减弱（P < 0.05）。干扰miR-181a表达后，A2780细胞对顺铂的抵抗作用减弱（P < 0.05），而上调miR-181a表达，A2780/DDP细胞对顺铂的抵抗作用增强（P < 0.05）。通过TargetScan、miRDB、miRwalk三个数据库预测到PRKCD可作为miR-181a下游靶基因，下调miR-181a表达可使PRKCD蛋白表达明显增强（P < 0.05）；反之，上调miR-181a表达能够显著抑制PRKCD蛋白表达（P < 0.05）。结论 miR-181a卵巢癌细胞对顺铂的耐药性方面具有抑制作用。
- 卵巢癌 /
- PRKCD /
- miR-181a /
- 顺铂耐药性
Abstract: Objective To investigate the effect of miR-181a on chemotherapy resistance of ovarian cancer and its regulatory mechanism. Methods Real-time PCR was used to detect the expression of miR-181a in A2780 and cisplatin resistant cell lines （A2780/DDP）, and siltation/overexpression changed the expression of miR-181a in A2780 and A2780/DDP cells. MTT method was used to determine the sensitivity of cells to cisplatin before and after the transfection. Three MicroRNA target gene databases, TargetScan, miRDB and miRwalk, were used to predict the downstream targets of miR-181a, and the changes in protein expression of target genes were analyzed by Western blot. Results Compared with A2780 cells, the expression of miR-181a in A2780/DDP cells was significantly decreased （P < 0.05）. After the transfection of A2780 cells with miR-181a inhibitor （interfering with Mir-181A expression）, the sensitivity of A2780 cells to cisplatin decreased （P < 0.05）, and after the transfection of A2780/DDP cells with miR-181a mimic （overexpressing miR-181a）, The sensitivity of cells to cisplatin was increased （P < 0.05）. It was predicted that PRKCD could be used as the downstream target gene of miR-181a by TargetScan, miRDB and miRwalk databases, and down-regulation of miR-181a expression could significantly enhance PRKCD protein expression （P < 0.05）. On the contrary, up-regulation of miR-181a significantly inhibited PRKCD protein expression （P < 0.05）. Conclusion miR-181a may inhibit cisplatin resistance of ovarian cancer cell A2780 by regulating PRKCD.
- Ovarian cancer /
- PRKCD /
- miR-181a /
- Cisplatin resistance

HTML全文

图 1 miR-181a在两种卵巢癌细胞中qRT-PCR结果

与A2780细胞比较，^*P < 0.05。

Figure 1. The expression of miR-181a mRNA in A2780 and A2780/DDP cells

下载: 全尺寸图片幻灯片

图 2 miR-181a在两种细胞中qRT-PCR结果

A：A2780细胞中miR-181a的mRNA相对表达量；B：A2780/DDP细胞中miR-181a的mRNA相对表达量。与空白对照组细胞比较，^*P < 0.05。

Figure 2. The transfection efficiency of miR-181a inhibitors and mimics

下载: 全尺寸图片幻灯片

图 3 miR-181a靶基因预测韦恩图

Figure 3. Venn diagram of screening differentially expressed genes

下载: 全尺寸图片幻灯片

图 4 PRKCD蛋白在两种卵巢癌细胞中Western blot结果

A：A2780细胞中PRKCD的Western blotting结果；B：A2780/DDP细胞中PRKCD的Western blotting结果。

Figure 4. Expression of PRKCD protein in A2780 and A2780/DDP cells

下载: 全尺寸图片幻灯片

表 1 A2780细胞在不同浓度顺铂作用下的MTT数值

Table 1. MTT results of A2780 cells treated with different concentrations of Cisplatin

组别	药物浓度(μmol/L)
组别	0	10	20	30	40	50
阴性对照组	96.48 ± 1.58	73.42 ± 1.82	52.36 ± 1.32	19.87 ± 2.63	11.28 ± 2.36	6.68 ± 1.72
低表达组	97.23 ± 1.22	86.72 ± 1.76*	79.52 ± 1.68*	69.86 ± 1.92*	49.62 ± 1.56*	20.27 ± 1.82*
t	−3.007	−12.026	−130.674	−121.951	−83.009	−235.386
P	0.10	0.01	< 0.001	< 0.001	< 0.001	< 0.001
与阴性对照组比较，^*P < 0.05。

下载: 导出CSV

表 2 A2780/DDP细胞在不同浓度顺铂作用下的MTT数值

Table 2. MTT results of A2780/DDP cells treated with different concentrations of Cisplatin

组别	药物浓度(μmol/L)
组别	0	10	20	30	40	50
阴性对照组	97.42 ± 1.42	92.85 ± 1.72	85.64 ± 1.87	82.48 ± 2.24	76.95 ± 1.98	61.12 ± 2.32
低表达组	97.16 ± 1.82	88.63 ± 1.87	84.72 ± 1.87	76.12 ± 1.87	59.72 ± 2.52	40.58 ± 2.78
t	1.126	48.728	0.6025	29.773	55.265	77.34
P	0.377	< 0.001	0.579	< 0.001	< 0.001	< 0.001

下载: 导出CSV

参考文献(26)

[1]	Amjadi M,Hallaj T,Hildebrandt N. A sensitive homogeneous enzyme assay for euchromatic histone-lysine-N-methyltransferase 2 (G9a) based on terbium-to-quantum dot time-resolved FRET[J]. Bioimpacts,2021,11(3):173-179.
[2]	Giordano M,Decio A,Battistini C,et al. L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling[J]. J ExpClin Cancer Res,2021,40(1):319.
[3]	Zhang X,Qin T,Zhu Z,et al. Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt/mTOR signaling[J]. Am J Med Sci,2020,359(2):123-129.
[4]	Hu Z,Cai M,Zhang Y,et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway[J]. Cell Cycle (Georgetown,Tex. ),2020,19(2):193-206.
[5]	Forouhari S,Mahmoudi E,Safdarian E,et al. MicroRNA:A Potential Diagnosis for Male Infertility[J]. Mini Rev Med Chem,2021,21(10):1226-1236. doi: 10.2174/1389557520999201209213319
[6]	Kim J,You S. Samul-tang ameliorates oocyte damage due to cyclophosphamide-induced chronic ovarian dysfunction in mice[J]. Sci Rep,2020,10(1):21925. doi: 10.1038/s41598-020-79013-7
[7]	Jacob H,Stanisavljevic L,Storli K E,et al. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer[J]. Oncotarget,2017,8(50):87837-87847. doi: 10.18632/oncotarget.21237
[8]	Huang F L,Liao E C,Li C L,et al. Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments[J]. Oncol Lett,2020,20(1):448-454. doi: 10.3892/ol.2020.11583
[9]	Al-Hazmi A. Antioxidant activity of silymarin in microcystin-LR cardiac and pulmonary induced injuries on mice[J]. Pak J Biol Sci,2020,23(11):1369-1373. doi: 10.3923/pjbs.2020.1369.1373
[10]	Lei B,Huang Y,Zhou Z,et al. Circular RNA hsa_circ_0076248 promotes oncogenesis of glioma by sponging miR-181a to modulate SIRT1 expression[J]. Cell Biochem,2019,120(4):6698-6708. doi: 10.1002/jcb.27966
[11]	Abramson E,Hardman C,Shimizu A J,et al. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation[J]. Cell ChemBiol,2021,28(4):537-545.e4.
[12]	Ning Li,Long Bo,Zhang Wen,et al. Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer[J]. Int J Oncol,2018,53(6):2637-2646.
[13]	Giampaolino P,Della Corte L,Foreste V,et al. Unraveling a difficult diagnosis: The tricks for early recognition of ovarian cancer[J]. Minerva Med,2019,110(4):279-291.
[14]	Ni J,Zhang X,Li J,et al. Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts[J]. Cell Death Dis,2021,12(12):1131.
[15]	Ahn J H,Lee H S,Lee J S,et al. Nc886 is induced by TGF-β and suppresses the microRNA pathway in ovarian cancer[J]. Nat Commun,2018,9(1):1166. doi: 10.1038/s41467-018-07818-2
[16]	王皓,周宇. 微小RNA在肝胆胰疾病中作用的研究进展[J]. 实用肝脏病杂志,2011,14(2):155-157. doi: 10.3969/j.issn.1672-5069.2011.02.033
[17]	De Paula Silva E,Marti L C,Andreghetto F M,et al. Extracellular vesicles cargo from head and neck cancer cell lines disrupt dendritic cells function and match plasma microRNAs[J]. Sci Rep,2021,11(1):18534. doi: 10.1038/s41598-021-97753-y
[18]	Gao Jianlong,Xia Silong. Reduced miR-519d-3p levels in the synovium and synovial fluid facilitate the progression of post-traumatic osteoarthritis by targeting VEGF[J]. Exp Ther Med,2021,22(6):1478. doi: 10.3892/etm.2021.10913
[19]	陈怡然. MicroRNA-181a靶向PRKCD调节子宫颈鳞癌化疗抵抗性的机制研究[D]. 上海: 复旦大学博士学位论文, 2013.
[20]	Ben-Mustapha I,Agrebi N,Barbouche M R. Novel insights into FAS defects underlying autoimmune lymphoproliferative syndrome revealed by studies in consanguineous patients[J]. J Leukoc Biol,2018,103(3):501-508.
[21]	Muscella A,Cossa L G,Vetrugno C,et al. Inhibition of ZL55 cell proliferation by ADP via PKC-dependent signalling pathway[J]. J Cell Physiol,2018,233(3):2526-2536. doi: 10.1002/jcp.26128
[22]	Omarjee O,Picard C,Frachette C,et al. Monogenic lupus:Dissecting heterogeneity[J]. Autoimmun Rev,2019,18(10):102361. doi: 10.1016/j.autrev.2019.102361
[23]	Munson M J,Mathai B J,Ng M Y W,et al. GAK and PRKCD are positive regulators of PRKN-independent mitophagy[J]. Nat Commun,2021,12(1):6101. doi: 10.1038/s41467-021-26331-7
[24]	Chun K H,Cho S J,Lee J W,et al. Protein kinase C-δ interacts with and phosphorylates ARD1[J]. J Cell Physiol,2021,236(1):379-391. doi: 10.1002/jcp.29866
[25]	Lothstein L,Soberman J,Parke D,et al. Pivarubicin is more effective than doxorubicin against triple-negative breast cancer in vivo[J]. Oncol Res,2020,28(5):451-465. doi: 10.3727/096504020X15898794315356
[26]	Chen Y,Ke G,Han D,et al. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD[J]. Exp Cell Res,2014,320(1):12-20. doi: 10.1016/j.yexcr.2013.10.014

相关文章(20)

[1]	赵丽珠, 董莹, 邓玥, 杨丽华. 基于单细胞测序技术分析上皮细胞相关基因与卵巢癌患者预后的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240402
[2]	王兴粉, 邓玥, 杨丽华. 卵巢癌脂质代谢相关基因预后模型的构建及免疫浸润分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240403
[3]	蒋亚萍, 杨宏英, 汪昊涵, 宁显灵, 杨谢兰. 不同肠道手术方式对肠道受侵上皮性卵巢癌患者预后的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230109
[4]	廉阳秧, 岳红萍, 端娅, 胡红文, 罗芳. miRNA-15a/16调控Bmi-1蛋白在卵巢癌顺铂化疗耐药中的作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231204
[5]	顾津伊, 邓德耀, 袁文丽, 杨秋萍, 宋健梅, 沈彦均, 郭媛媛, 徐红云. 2014年～2020年鲍曼不动杆菌的临床分布及耐药性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220504
[6]	张丽菊, 姜晓明, 陈昌贤, 吴喜, 张振勇, 刘为军. 长链非编码RNA-p21调控微小RNA-9/去乙酰化酶1信号通路逆转结直肠癌细胞奥沙利铂耐药性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220519
[7]	杨霄彦, 郝春光, 张志坚. 孕激素通过HOXA9对人卵巢癌细胞增殖和迁移的机制研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221022
[8]	邓玥, 邹丹, TounaAbdelkerim Barh, 杨丽华. 基于Oncomine 数据库研究PDE4D基因在卵巢癌中的表达及血根碱的调控作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220303
[9]	龚容, 孙威, 徐从琼, 刘霖, 王娟, 晋臻. 3584株分离自尿液的大肠埃希菌的耐药性分析, 昆明医科大学学报.
[10]	王春龙, 韩丹, 文亮. 间皮素与肿瘤诊治的相关研究进展, 昆明医科大学学报.
[11]	胡玉崇, 陆景坤, 崔梦瑶. PTEN及Caspase-3可能参与卵巢癌铂类耐药的机制, 昆明医科大学学报.
[12]	胡万芹, 赵洪波, 梁宏, 赵庆华, 杨丽华. 顺铂耐药卵巢癌的差异表达基因和信号通路富集分析, 昆明医科大学学报.
[13]	王杨. 昆明地区铜绿假单胞菌ESBLs基因型和耐药性研究, 昆明医科大学学报.
[14]	马锦华. 84例慢性牙周炎患者病变牙袋内厌氧菌分布及耐药性分析, 昆明医科大学学报.
[15]	经晓杰. 急诊重症监护病房革兰阴性杆菌感染分布及耐药性, 昆明医科大学学报.
[16]	杨涵. Bmi-1基因在不同类型上皮性卵巢癌组织中的表达及临床意义, 昆明医科大学学报.
[17]	李晓非. 噬菌体生物扩增技术在结核分枝杆菌利福平耐药性检测中的应用, 昆明医科大学学报.
[18]	杨丽华. 抗整合素αⅤβ3单抗抑制上皮性卵巢癌血管及肿瘤生成的实验研究, 昆明医科大学学报.
[19]	. 2009年楚雄州人民医院病原菌分布及耐药性分析, 昆明医科大学学报.
[20]	. 顺铂同期放化疗治疗局部晚期宫颈癌的疗效观察, 昆明医科大学学报.